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Abstract. 
 
We used immunofluorescence techniques 
and confocal imaging to study the organization of the 
 
membrane skeleton of skeletal muscle fibers of 
 
mdx
 
 
mice, which lack dystrophin. 
 
b
 
-Spectrin is normally 
found at the sarcolemma in costameres, a rectilinear ar-
ray of longitudinal strands and elements overlying Z 
and M lines. However, in the skeletal muscle of 
 
mdx
 
 
mice, 
 
b
 
-spectrin tends to be absent from the sarco-
lemma over M lines and the longitudinal strands may 
be disrupted or missing. Other proteins of the mem-
brane and associated cytoskeleton, including syntro-
phin, 
 
b
 
-dystroglycan, vinculin, and Na,K-ATPase are 
also concentrated in costameres, in control myofibers, 
and 
 
mdx 
 
muscle. They also distribute into the same al-
tered sarcolemmal arrays that contain 
 
b
 
-spectrin. Utro-
phin, which is expressed in 
 
mdx 
 
muscle, also codistrib-
utes with 
 
b
 
-spectrin at the mutant sarcolemma. By 
contrast, the distribution of structural and intracellular 
membrane proteins, including 
 
a
 
-actinin, the Ca-ATP-
ase and dihydropyridine receptors, is not affected, even 
at sites close to the sarcolemma. Our results suggest 
that in myofibers of the 
 
mdx
 
 mouse, the membrane-
associated cytoskeleton, but not the nearby myoplasm, 
undergoes widespread coordinated changes in organi-
zation. These changes may contribute to the fragility of 
the sarcolemma of dystrophic muscle.
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D
 
YSTROPHIN
 
 is the protein that is missing or mutated
in patients with Duchenne or Becker muscular
dystrophy (for review see 22, 23) and in the 
 
mdx
 
mouse (6, 80). The absence of dystrophin is believed to
weaken the sarcolemma, which becomes more susceptible
to damage during the contractile cycle (22, 52, 74). How
dystrophin stabilizes the sarcolemma of healthy muscle fi-
bers and how its loss destabilizes the sarcolemma of dys-
trophic fibers are still poorly understood, despite the ex-
tensive molecular characterization of dystrophin and its
ligands.
Molecular cloning and sequencing of dystrophin place it
in the spectrin superfamily of cytoskeletal proteins (1, 15,
17, 40, 43). Like other members of this superfamily, in-
cluding 
 
a
 
-actinin and 
 
b
 
-spectrin, dystrophin has an NH
 
2
 
-
terminal domain that binds actin and a central rod domain
composed of a series of triple helical repeats. Like 
 
a
 
-acti-
nin and 
 
a
 
-spectrin, dystrophin has a sequence in its COOH-
terminal region containing EF hands. The COOH-termi-
nal domain of dystrophin also binds a complex of integral
membrane glycoproteins that includes dystroglycan and
the sarcoglycans (8, 35, 57, 85). Analysis of the severity of
the myopathies caused by different mutations of dystro-
phin in humans and in transgenic 
 
mdx
 
 mice suggests that
changes limited to the central rod domain and the actin-
binding domain have relatively modest effects. However,
changes that inhibit binding to the glycoprotein complex
are associated with the severest forms of dystrophy (10, 24,
65, 84).
Some of these changes associated with binding to the
glycoprotein complex are likely to be related to extracellu-
lar structures, as dystroglycan (also known as cranin) binds
laminin with high affinity (26, 35, 70). Thus, the dystro-
phin–glycoprotein complex has the potential of linking ac-
tin in the sarcomeres of superficial myofibrils through dys-
trophin and the trans-sarcolemmal glycoprotein complex,
to laminin in the basal lamina of the muscle fiber. This role
of the dystrophin–glycoprotein complex is consistent with
the observation that dystrophin is concentrated at the sar-
colemma of skeletal muscle fibers in costameres, regions
of the sarcolemma that overlie Z and M lines, as well as in
longitudinally oriented strands (47, 49, 62, 73). Costameres
are believed to be involved in linking the contractile appa-
ratus to the basal lamina (60, 69, 75). Thus, they may serve
to transmit the force of contraction to extracellular ele-
ments (75). Mutations that alter this linkage would be ex-
pected to alter the stresses on the sarcolemma that occur
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during contraction, perhaps resulting in tears in the mem-
brane that lead to the formation of delta lesions (52). This
force transmission model for the damage caused in muscu-
lar dystrophy is consistent with nearly all the current struc-
tural and genetic evidence with one notable exception: it
does not account for the mild effects of mutations affect-
ing dystrophin-actin binding.
As an alternative to this model for the physiological role
of dystrophin, we are examining the possibility that the
fragility of the sarcolemma in dystrophic myofibers is
linked to changes in the organization of the membrane-
associated cytoskeleton. Dystrophin is only one of several
structural proteins that underlie and support the sarco-
lemma. We hypothesize that, in the absence of dystrophin,
changes in the organization of these other structural pro-
teins may leave the sarcolemma vulnerable to damage.
This idea is based on earlier observations that 
 
b
 
-spectrin
and vinculin colocalize with dystrophin in the costameres
of skeletal muscle fibers (62). Furthermore, our earlier
results suggested that, although 
 
b
 
-spectrin remained asso-
ciated with the sarcolemma in human and mouse muscle
fibers that lacked dystrophin, its distribution at the mem-
brane was abnormal (62; see also 20, 50). Here we provide
morphological evidence that the membrane skeletal pro-
teins of dystrophic, 
 
mdx
 
 mice codistribute in abnormal sar-
colemmal structures. These morphological changes leave
extensive regions of the membrane with little apparent
support from the membrane skeleton and may contribute
to the fragility of the sarcolemma of dystrophic muscle.
 
Materials and Methods
 
Animals
 
All mice (Jackson Laboratories) used were male C57-black-10smsc-
DMD-
 
mdx
 
 mice and control littermates aged 6 mo.
 
Tissue for Immunofluorescence
 
Animals were anesthetized by intraperitoneal injection of a combination
of ketamine (80 mg/kg) and xylazine (7 mg/kg). Fixed tissue was obtained
by perfusing the anesthetized animal through the left ventricle with a solu-
tion of 2% paraformaldehyde in PBS (10 mM NaP, 145 mM NaCl, pH
7.2). Fast twitch muscles, including the tibialis anterior, extensor digi-
torum longus, and quadriceps muscles, were dissected; the quadriceps
muscle was incubated for an additional 5 min in 2% paraformaldehyde in
PBS. Tissue was blotted dry and placed on a cryostat chuck in O.C.T.
mounting medium (4583 tissue tek; Skura Finetek USA, Inc.). The chuck
was plunged into a slush of liquid nitrogen, generated under vacuum. 20-
 
m
 
m-thick sections were cut on a cryostat (model 2800, Frigocut, Reichart-
Jung, Cambridge Instruments), collected on glass slides coated with 0.5%
gelatin and 0.05% chromium potassium sulfate, and stored desiccated at
 
2
 
70
 
8
 
C.
For the preparation of unfixed longitudinal sections, tissue was ob-
tained without perfusion, mounted, frozen, and cryosectioned as above.
To prevent contraction, the frozen sections were collected on the surface
of an ice-cold bath of PBS containing 10 mM EGTA, pH 7.4. Sections
were rapidly lifted from the surface of the bath directly onto gelatin-
coated slides. Unfixed longitudinal sections were cut fresh for each exper-
iment and used immediately.
 
Antibodies
 
Mouse mAbs (Novocastra Laboratories) to the COOH terminus (amino
acids 3669–3685) of human dystrophin (Dys2; ref. 54), to the COOH ter-
minus of human 
 
b
 
-dystroglycan (5), and to a fusion protein containing the
NH
 
2
 
-terminal region of utrophin (NCL-DRP-2; ref. 4) were used at dilu-
tions of 1:5, 1:10, and 1:5, respectively. An mAb against all known syntro-
phin isoforms, 1351, was provided by Dr. S. Froehner (University of North
Carolina, Chapel Hill, NC), and was used at 16 
 
m
 
g/ml. Mouse mAbs (Af-
finity Bioreagents) against the 
 
a
 
 subunit of the dihydropyridine receptor
(DHPR
 
1
 
; clone 1A), and the sarcoplasmic/endoplasmic reticulum Ca-ATP-
ase from rabbit skeletal muscle (SERCA 1) were used at dilutions of 1:200
and 1:100, respectively. Mouse mAbs against 
 
a
 
-actinin from rabbit skele-
tal muscle (EA-53) and vinculin from chicken gizzard (VIN-11-5; both
from Sigma Immuno Chemicals) were used at dilutions of 1:200 and 1:50,
respectively.
The rabbit polyclonal antibody, 9050, was prepared against purified hu-
man erythrocyte 
 
b
 
-spectrin. It was affinity-purified over a column of
erythrocyte 
 
b
 
-spectrin and cross-adsorbed against 
 
b
 
-fodrin and 
 
a
 
-fodrin,
purified from bovine brain as previously described (63, 87). Antibodies to
erythrocyte 
 
b
 
-spectrin were also generated in chickens. IgY was purified
from egg yolk using the EggStract kit (Promega Corp.) and anti–
 
b
 
-spec-
trin antibodies were affinity-purified as described (63). Specificity for
 
b
 
-spectrin was demonstrated by immunoblotting (Ursitti, J.A., L. Martin,
W.G. Resneck, T. Chaney, C. Zielke, B.E. Alger, and R.J. Bloch, manu-
script submitted for publication). Both affinity-purified antibodies to
 
b
 
-spectrin were used at 3 
 
m
 
g/ml. Polyclonal rabbit antibodies to a fusion
protein containing residues 335–519 of the 
 
a
 
1 subunit of the Na,K-ATP-
ase and to a fusion protein containing residues 338–519 of the 
 
a
 
2 subunit
of the Na,K-ATPase (Upstate Biotechnologies) were used at 3 
 
m
 
g/ml.
Nonimmune mouse mAbs, MOPC21, were obtained from Sigma
Chemical Co. Nonimmune chicken IgY was purified from preimmune
controls collected from the same chickens and used to generate the anti–
 
b
 
-spectrin antibodies. Normal rabbit serum was purchased from Jackson
ImmunoResearch Laboratories.
Secondary antibodies included goat anti–rabbit and goat anti–mouse
IgGs, and donkey anti–chicken IgY. All secondary antibodies (Jackson
ImmunoResearch) as fluorescein or tetramethylrhodamine conjugates
were species-specific with minimal cross-reactivity and were used at a di-
lution of 1:100.
The specificities of all these antibodies have been established by immu-
noblotting or immunoprecipitation, as reported by the suppliers or in the
relevant publications.
 
Fluorescent Immunolabeling
 
Sections were incubated in PBS/BSA (PBS containing 1 mg/ml BSA and
10 mM NaN
 
3
 
) for 15 min to reduce nonspecific binding and placed in pri-
mary antibody in PBS/BSA for 2 h at room temperature, or overnight at
4
 
8
 
C. Samples were washed with PBS/BSA and incubated for 1 h with fluo-
rescein– or tetramethylrhodamine–conjugated secondary antibodies di-
luted in PBS/BSA. After additional washing, samples were mounted in a
solution containing nine parts glycerol, one part 1 M Tris-HCl, pH 8.0,
supplemented with 1 mg/ml 
 
p
 
-phenylenediamine to reduce photobleach-
ing (37). Slides were observed with a Zeiss 410 confocal laser scanning
microscope (Carl Zeiss, Inc.) equipped with a 63
 
3
 
 NA 1.4 plan-apochro-
matic objective. The pinholes for both fluorescein and tetrameth-
ylrhodamine fluorescence were set to 18. Images were collected and
stored with software provided by Zeiss.
To generate figures, images were arranged into montages, labeled, and
given scale bars with Corel Draw 6 (Corel Corporation Ltd.). Inset pic-
tures were prepared with MetaMorph (Universal Imaging) and magnified
twofold with Corel Draw 6. No other processing was used on any of the
images.
For the quantitations shown in Fig. 3, images were prepared by one of
the authors and scored double blind by the other. Images were taken of all
sarcolemmal regions in controls and 
 
mdx
 
 myofibers that did not show ob-
vious tears, holes, or other processing artifacts. Sampling was otherwise
random. Images of control and 
 
mdx
 
 sarcolemma were coded and mixed
randomly. Each image was then evaluated for the pattern of 
 
b
 
-spectrin
distribution that was most common over the region of the sarcolemma in
clear focus. Images were sorted into one of four categories: clear cos-
tameric distribution, including regular labeling over Z and M lines and in
longitudinal domains; label present at Z lines, but absent over M lines or
in longitudinal domains; label present at Z lines but absent both over M
lines and in longitudinal domains; and label absent at Z lines, M lines, and
longitudinal domains, but present in polygonal arrays or other irregular
structures. We obtained consistent results when other naive observers
scored the same or a similar set of images.
 
1. 
 
Abbreviations used in this paper:
 
 DHPR, dihydropyridine receptor;
SERCA, Ca-ATPase of the sarcoplasmic reticulum. 
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Materials
 
Unless otherwise stated, all materials were purchased from Sigma Chemi-
cal Co. and were the highest grade available.
 
Results
 
We used immunofluorescence labeling and confocal mi-
croscopy to examine the distribution of several membrane
skeletal proteins in longitudinal sections through the sar-
colemma of fast twitch muscle fibers from the dystrophic
 
mdx
 
 mouse. The use of confocal optics allowed us to iso-
late the fluorescence signal arising from proteins located
within 
 
z
 
1.2 
 
m
 
m of the sarcolemmal bilayer (83), thereby
reducing any fluorescence signals, specific or nonspecific,
associated with structures lying deeper in the myoplasm.
Each of the sarcolemmal proteins we examined has been
shown to be concentrated in costameres, together with
dystrophin and 
 
b
 
-spectrin (12, 32, 47, 49, 59, 62, 73; Wil-
liams, M.W., and R.J. Bloch, manuscript in preparation).
We limited our observations to fast twitch fibers because
the rectilinear pattern generated by immunolabeling of
membrane skeletal elements at the sarcolemma, overlying
Z and M lines and in longitudinally oriented strands, is
much more clearly defined than in slow twitch fibers (Wil-
liams, M.W., and R.J. Bloch, manuscript in preparation).
In addition, fast twitch fibers are more susceptible to dam-
age associated with dystrophinopathies (82).
 
b
 
-Spectrin in mdx Muscle
 
Longitudinal cryosections were prepared from the quadri-
ceps muscle of control and 
 
mdx
 
 mice. Sections from con-
trol and 
 
mdx
 
 samples were placed on the same slides and
were treated simultaneously during all stages of our exper-
iments. We first labeled sections with 9050, an affinity-
purified polyclonal antibody against 
 
b
 
-spectrin, and Dys2,
an mAb against dystrophin. Primary antibodies were visu-
alized with species-specific secondary antibodies coupled
to either fluorescein or tetramethylrhodamine. In controls,
 
b
 
-spectrin was found in costameres, areas overlying the Z
lines and M lines, and in longitudinally oriented strands
(Fig. 1 A, arrows and arrowheads indicate examples of
each of these structures), as we reported previously (62;
see also 12). In our samples, costameres overlying Z and
M lines could be distinguished under fluorescence illumi-
nation by the fact that structures over Z lines were usually
wider than those over M lines (62). Labeling of all these
structures was specific, as it was not obtained in either
wild-type (Fig. 1, G and H) or 
 
mdx
 
 tissue (Fig. 1, K and L)
with nonimmune rabbit antibodies or with a secondary an-
tibody that failed to bind rabbit IgG. Dystrophin, recog-
nized by labeling with Dys2, was also enriched in cos-
tameres (Fig. 1 B), as previously reported (47, 49, 62, 73).
The distribution of 
 
b
 
-spectrin in the quadriceps of the
 
mdx 
 
mouse differed significantly from that in control mus-
cles. Although in some cases the 
 
b
 
-spectrin distribution
was very similar to that seen in the control tissue (Fig. 2,
normal rectilinear distribution) such examples were rare
in 
 
mdx
 
 muscle (
 
,
 
3% of 108 fibers scored double blind).
Many of the samples (
 
z
 
36%) failed to show labeling for
 
b
 
-spectrin either over M lines (Fig. 2, E and F) or in longi-
tudinally oriented strands (Fig. 2, C and D). Approxi-
mately the same proportion of 
 
mdx
 
 fibers (
 
z
 
42%) failed
to show labeling of both these structures (Fig. 2, G and H),
and so retained organized domains of 
 
b
 
-spectrin only over
Z lines. This pattern of labeling is similar to that reported
by Porter et al. (62), Minetti et al. (50), and Ehmer et al.
(20). The 
 
mdx
 
 muscle fibers that could not be placed into
any of the above categories showed different morpholo-
gies, including small irregular boxes, zig-zag patterns, or
polygonal arrays (Fig. 2, I–L). Some regions of the sarco-
lemma of 
 
mdx
 
 muscle lacking visible 
 
b
 
-spectrin extended
over several sarcomeres (Fig. 2 J, inset) or encompassed
large areas (
 
.
 
50 
 
m
 
m
 
2
 
) of the sarcolemma between Z lines
(Fig. 2 H). The fact that all of these patterns were associ-
ated with muscle fibers that lacked dystrophin was con-
firmed by double immunofluorescence studies with anti–
 
b
 
-spectrin and Dys2 anti-dystrophin. The latter antibody
did not label any structures at the sarcolemma of the dys-
trophic muscle fibers studied here (not shown).
In contrast to our results with 
 
mdx 
 
muscle fibers, we
found that 
 
.
 
75% of control myofibers had regular recti-
linear distributions of 
 
b
 
-spectrin at the sarcolemma (Figs.
1 A and 2 A), with prominent elements in longitudinal
strands and overlying Z and M lines. Most of the remain-
ing control fibers were not labeled at the sarcolemma ei-
ther over M lines or in longitudinal domains. Only one
control fiber out of the 72 that we scored did not show la-
beling of the sarcolemma over M lines or longitudinal do-
mains. We found no control fibers with irregular boxes,
polygonal arrays, or zig-zag patterns as seen in 
 
mdx
 
. Typi-
cally, the regions of the control sarcolemma that failed to
label with antibodies to 
 
b
 
-spectrin extended over areas of
only 1–2 
 
m
 
m
 
2
 
 (the area enclosed by adjacent Z and M lines
and a pair of well-spaced longitudinal strands) in control
muscle fibers. In very few cases (
 
,
 
1% of all fibers in con-
trols and 
 
mdx
 
), we found regions of the sarcolemma of
muscle fibers that showed little or no organization of the
sarcolemma. These may represent regions that were
poorly preserved or damaged during processing.
The altered arrangement of proteins at the sarcolemma
of dystrophic muscle fibers was not due to differences in
fixation or labeling of these fibers. We routinely examined
samples that were fixed by perfusion in situ before the
muscle was dissected and cryosectioned, as well as samples
that were unfixed and collected under conditions that pre-
vented contraction following cryosectioning (see Materials
and Methods). To examine their possible effects, we also
varied the perfusion and fixation regimens. We found no
significant differences among these samples, suggesting
that our results were independent of the methods we used.
Furthermore, control and 
 
mdx
 
 samples were matched for
age and sex, so these factors did not contribute to the dif-
ferences in sarcolemmal organization. Finally, most con-
trol and 
 
mdx 
 
samples were also collected, frozen, sec-
tioned, and stained together. Therefore, this ruled out the
possibility that differences in handling could account for
the morphological changes we observed. These results
suggest that the organization of 
 
b
 
-spectrin at the sarco-
lemma of 
 
mdx
 
 is altered from the control. The differences
between the 
 
mdx
 
 and control samples, summarized in Fig.
3, are highly significant (
 
P
 
 
 
, 
 
0.0001 by 
 
x
 
2
 
 analysis). 
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Figure 1. Immunolabeling of b-spectrin and dystrophin in wild-type and mdx muscle. Perfusion-fixed quadriceps muscles from wild-
type (A–C, G–J) and mdx mice (D–F, K–N) were snap frozen, and cryosectioned (see Materials and Methods). The sections were dou-
ble-labeled with affinity-purified rabbit antibodies (9050) to b-spectrin (A and D) and with the mouse mAb, Dys2, to dystrophin (B and
E). Typical costameric structures overlying a Z line (thick arrow), an M line (thin arrow), and in a longitudinal strand (double arrow-
heads) are indicated in A. Color composite images were created to show b-spectrin in green, dystrophin in red, and areas containing
both proteins in yellow (C and F). These images show extensive overlap of labeling for b-spectrin and dystrophin in costameres of wild-
type (C) but not mdx (F) muscle. Controls were double-labeled with 9050 (G and K) and MOPC21, a nonimmune mouse mAb (H and
L), or with a mouse mAb to a-actinin (I and M) and normal rabbit serum (J and N). Control samples, imaged under conditions identical
to those used in A–F, showed little nonspecific labeling or bleedthrough of fluorescence. This was also true for the mdx sample shown in
D–F. Bars, 5 mm. 
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Other Membrane-Skeletal Proteins
 
Unfixed longitudinal cryosections of quadriceps muscle
from control and 
 
mdx
 
 animals were labeled in double im-
munofluorescence protocols for 
 
b-spectrin, with either
9050 or chicken anti–b-spectrin antibodies, and with anti-
bodies to other integral membrane or cytoskeletal pro-
teins, including syntrophin, b-dystroglycan, vinculin, utro-
Figure 3. Quantitation of b-spectrin pat-
terns in mdx fibers. Images of samples
processed, as in Fig. 2, were evaluated
double blind for the dominant patterns of
b-spectrin distribution. Afterwards they
were sorted into four categories: A, clear
costameric distribution, including regular
labeling over Z lines and M lines, and in
longitudinal domains; B, labeling absent
over M lines or in longitudinal domains;
C, labeling absent both over M lines and
in longitudinal domains; and D, labeling
of polygonal arrays or other structures
that do not demonstrate regular labeling
over Z lines. 108 mdx fibers and 72 control
fibers were examined. Closed bars: con-
trols; open bars: mdx.
Figure 2. Altered distribution of b-spectrin at
the sarcolemma of mdx muscle fibers. Samples
were processed as in Fig. 1 and labeled with 9050
rabbit anti–b-spectrin antibodies. Control fibers
show a clear costameric distribution for b-spec-
trin (A). Fibers from the mdx mouse show a
range of distributions of b-spectrin (B–L), from
normal (B) to highly altered (J–L). In most mdx
fibers, b-spectrin was depleted or missing at the
sarcolemma in longitudinal domains (C and D),
overlying M lines (E and F), or both (G and H).
In some regions, b-spectrin could not be de-
tected at the sarcolemma overlying some Z lines
(I–L), which led to the formation of zig-zag pat-
terns (I and J) or polygonal arrays (K and L).
Bars, 5 mm. Inserts show the regions enclosed by
white boxes at twofold magnification.The Journal of Cell Biology, Volume 144, 1999 1264
phin, and the a1 and a2 subunits of the Na,K-ATPase.
Structures labeled by primary antibodies were visualized
with species-specific secondary antibodies coupled to ei-
ther fluorescein or tetramethylrhodamine.
The  a1 and a2 subunits of the Na,K-ATPase form a
complex with ankyrin and b-spectrin at the sarcolemma of
skeletal muscle fibers (Williams, M.W., and R.J. Bloch,
manuscript in preparation). This results in the codistribu-
tion of the two subunits of the Na,K-ATPase with b-spec-
trin in costameres (for a typical control, see Fig. 4, A–C).
Therefore, we expected both subunits to redistribute with
b-spectrin at the sarcolemma of mdx muscle. This predic-
tion was confirmed by double immunofluorescence exper-
iments (a1: Fig. 4, D–F; a2: Fig. 4, G–I). We observed ex-
tensive overlap in the distributions of these proteins with
b-spectrin (Fig. 4, C and F; in the color overlays, red repre-
sents the Na,K-ATPase, green represents b-spectrin and
yellow represents regions containing both proteins). The
absence of labeling at regions overlying M lines, the dis-
ruption of longitudinally oriented strands and structures
overlying Z lines, and the presence of irregular polygonal
structures were evident in the patterns of labeling of the
a1 and a2 subunits of the Na,K-ATPase, as they were for
b-spectrin.
b-Dystroglycan is the transmembrane glycoprotein of
the dystrophin-associated glycoprotein complex that binds
dystrophin (39, 77). Syntrophin is a peripheral membrane
protein that binds to dystrophin at sites COOH-terminal
to those recognized by b-dystroglycan (2, 9). In control
muscle fibers, both syntrophin and b-dystroglycan are en-
riched in costameres (Williams, M.W., and R.J. Bloch,
manuscript in preparation), as previously reported for dys-
Figure 4. Altered distribution of the Na,K-ATP-
ase at the sarcolemma of mdx muscle. Unfixed
quadriceps muscles of wild-type (A–C, J–M) and
mdx (D–I, N–Q) mice were snap frozen and sec-
tioned on a cryostat. Experimental samples (A–I)
were double-labeled with affinity-purified chicken
antibodies to b-spectrin (B, E, and H) and poly-
clonal rabbit antibodies to the a1 (A and D) or
a2 (G) subunits of the Na,K-ATPase. In color
composite images, the a1 or a2 subunits are rep-
resented in red, b-spectrin in green, and sites
containing both proteins in yellow. (A–C)
b-Spectrin and the a1 subunit of the Na,K-ATP-
ase colocalize in costameres in control muscle fi-
bers. Similar results were obtained with the a2
subunit of the Na,K-ATPase (not shown). (D–I)
The distribution of the a1 (D) and a2 (G) sub-
units of the Na,K-ATPase at the sarcolemma is
altered, but these subunits still colocalize with
the  b-spectrin (yellow structures in F and I). (J–Q)
Controls were double-labeled either with nonim-
mune chicken IgY (K and O) and rabbit antibod-
ies to the a1 subunit of the Na,K-ATPase (J and
N), or with normal rabbit serum (L and P) and
chicken anti–b-spectrin (M and Q). No nonspe-
cific labeling or bleedthrough of fluorescence
was observed. Bars, 5 mm.Williams and Bloch Reorganization of the Sarcolemma of Dystrophic Myofibers 1265
trophin itself (see above). In mdx tissue, the amounts of
b-dystroglycan and syntrophin decrease significantly, but
low levels of both proteins can still be found at the sarco-
lemma (7, 56, 58). We used mAbs against b-dystroglycan
or syntrophin together with 9050 anti–b-spectrin to label
longitudinal sections of mdx muscle. Both syntrophin and
b-dystroglycan were enriched in costameric structures at
the sarcolemma that lacked longitudinal strands and ele-
ments overlying M lines, as well as in regions of the sarco-
lemma that were more severely altered (Fig. 5, A and D).
Comparison of b-spectrin with either b-dystroglycan or
syntrophin demonstrated extensive colocalization (Fig. 5,
C and F). Thus, the reduced amounts of syntrophin and
b-dystroglycan at the sarcolemma of mdx muscle codistrib-
uted in the membrane skeleton together with b-spectrin.
Vinculin is a protein involved in the attachment of actin
filaments to the membrane at focal adhesions (28) that is
also found in costameres in skeletal muscle fibers (59, 69),
where it codistributes with b-spectrin and dystrophin (62).
We labeled mdx tissue with anti-vinculin mAbs and with
9050 anti–b-spectrin. We found that the distribution of
vinculin was also altered at the sarcolemma of the mdx
mouse. Like the proteins studied above, vinculin was
much less regularly organized in mdx muscle than in con-
trol muscle, with gaps appearing because of the loss of
longitudinal domains or domains overlying Z or M lines.
Vinculin continued to colocalize with b-spectrin in these
altered structures (Fig. 5, G–I). This result contradicts a re-
cent report (51) stating that the organization of dystrophin,
but not vinculin, was altered at the sarcolemma of muscle
fibers from patients with Becker muscular dystrophy.
We also examined the distribution of utrophin ex-
pressed in mdx muscle (42, 46, 48, 86). Recent results with
muscles that lack both dystrophin and utrophin (16, 30)
support the idea that the expression of low levels of utro-
phin in mdx muscle may protect it from the severe damage
seen in Duchenne patients (79). Labeling of mdx muscle
by anti-utrophin antibodies was apparent over wide areas
of the sarcolemma in the same kinds of altered arrays as
described above. When we compared the distribution of
utrophin to that of b-spectrin by double label immunoflu-
orescence, utrophin codistributed with b-spectrin at the
sarcolemma (Fig. 5, J–L).
Control experiments ensured that our observations
Figure 5. Altered distribution of syntrophin, b-dys-
troglycan, utrophin, and vinculin at the sarco-
lemma of mdx muscle. Perfusion-fixed quadri-
ceps muscles from mdx mice were processed as
in Fig. 2 and double-labeled with affinity-puri-
fied rabbit antibodies to b-spectrin (9050: B, E,
H, and K) and mouse mAb to syntrophin (A),
b-dystroglycan (D), vinculin (G), or utrophin
(J). In composite pictures (C, F, I, and L),
b-spectrin is shown in green, the other protein in
red, and regions containing both proteins in yel-
low. The distribution of each of these proteins is
altered in mdx muscle, but each continues to
colocalize with b-spectrin (yellow structures in
C, F, I, and L). Bars, 5 mm.The Journal of Cell Biology, Volume 144, 1999 1266
were not due to cross-reaction of the species-specific sec-
ondary antibodies with inappropriate primary antibodies,
or to bleedthrough of the fluorescent label from one chan-
nel into another (Fig. 1, G–L; Fig. 4, J–M). Antibodies to
b-spectrin generated in chickens and used to label mdx
and wild-type muscle, together with appropriate controls,
gave the same results. Thus, it is unlikely that the coinci-
dent labeling for b-spectrin and the other membrane skel-
etal proteins at the sarcolemma of wild-type or mdx mus-
cle fibers was artifactual. Therefore, our results suggest
that several proteins that codistribute with b-spectrin in
costameres at the sarcolemma of healthy muscle also co-
distribute with b-spectrin in the irregularly organized
membrane skeleton of mdx myofibers.
Intracellular Proteins
The changes we observed in the organization of the sarco-
lemma might simply reflect extensive changes in the cy-
toarchitecture of dystrophic myofibers (52). To assess the
effects of the mdx phenotype on the organization of intra-
cellular structures lying near the dystrophic sarcolemma,
we used antibodies to a-actinin and to two integral mem-
brane proteins of intracellular membranes, coupled with
confocal laser scanning microscopy. a-Actinin is the main
component of the Z disc and may be involved in anchoring
the connections between the costamere and the contractile
apparatus near the Z line (for review see 71, 76). Double
labeling with mouse mAbs to the sarcomeric form of
a-actinin and rabbit antibodies against b-spectrin (9050)
showed a-actinin distributed normally at Z lines (Fig. 6 J),
even at sites near the sarcolemma that showed highly dis-
rupted patterns of labeling for b-spectrin (Fig. 6 K). Thus
a-actinin does not become disorganized in mdx muscle,
even at Z lines that are in close proximity to areas of the
dystrophic sarcolemma with abnormal membrane skeletal
arrays.
The Ca-ATPase of the sarcoplasmic reticulum (SERCA)
and DHPR of the transverse tubules are also readily studied
in double label immunofluorescence protocols. SERCA is
normally distributed in tubular elements surrounding the
Z line and M lines, as well as in elements aligned with the
Figure 6. Unaltered distribution of intracel-
lular proteins near the sarcolemma of mdx
muscle. Samples of wild-type (A–C) and mdx
(D–L) muscle were labeled with rabbit anti–
b-spectrin 9050 (B, E, H, and K) and mouse
mAb to SERCA (A and D), DHPR (G), or
a-actinin (J). In composite images, b-spectrin
is shown in green, the other proteins in red,
and regions in the confocal plain that contain
both proteins in yellow. (A–C) Near the sar-
colemma of wild-type mouse skeletal muscle,
SERCA is concentrated around Z lines, with
additional elements around M lines and in
longitudinally oriented domains. Labeling for
SERCA in the sarcoplasmic reticulum
around the M and Z lines appears to coincide
with  b-spectrin in the nearby sarcolemma
(yellow structures in C), because of the z1.2-
mm depth of the confocal plane sampled. La-
beling in longitudinally oriented structures
in the sarcoplasmic reticulum containing
SERCA and similar structures at the sarco-
lemma containing b-spectrin are apparently
not coordinated (red and green structures in
C). (D–F) The concentration of SERCA in
the sarcoplasmic reticulum at the levels of the
Z and M lines, and in longitudinally oriented
structures, does not change in the vicinity of
the mdx sarcolemma, which shows an altered
distribution of b-spectrin. (G–I) DHPR is
normally concentrated in the t-tubules that
surround each sarcomere at the A–I junction
(see text). This also holds for t-tubules sur-
rounding the A–I junctions of the myofibrils
that lie near the mdx sarcolemma, despite the
fact that the distribution of b-spectrin at the
sarcolemma is changed. (J–L) a-Actinin is
normally concentrated in the Z disk (see text;
Fig. 1); its distribution at Z disks of myofibrils
in the vicinity of the mdx sarcolemma is not
changed. Bars, 5 mm.Williams and Bloch Reorganization of the Sarcolemma of Dystrophic Myofibers 1267
longitudinal axis of the myofibers (Fig. 6, A–C). DHPR is
easily visualized in mammalian muscle as a double line at
the junctions of the A and I bands, where the transverse
tubules surround each sarcomere, including those near the
sarcolemma (38; for review see 25). The distributions of
both these membrane proteins showed no evidence of an
altered organization in mdx fibers, even when they were
examined in the same confocal plane as the dystrophic sar-
colemma, visualized with 9050 anti–b-spectrin (SERCA:
Fig. 6, D–F; DHPR, Fig. 6, G–I). These results suggest that
the changes in the organization of muscle fibers in adult
mdx mice are limited to the sarcolemma and closely asso-
ciated proteins. This is consistent with ultrastructural stud-
ies that reveal little change in the sarcoplasm of adult mdx
muscle (13, 80).
Discussion
We used immunofluorescence labeling and confocal mi-
croscopy to examine the distribution of membrane skele-
tal proteins in healthy and dystrophic (mdx) mouse mus-
cle. Our experiments were designed to test the hypothesis
that the absence of dystrophin is accompanied by exten-
sive changes in the organization of the sarcolemma. Our
results strongly support this hypothesis by demonstrating
widespread and potentially significant changes in the dis-
tribution of several peripheral and integral membrane
proteins at the sarcolemma. Surprisingly, all the proteins
we examined continued to codistribute at the altered sar-
colemma despite the absence of dystrophin.
Earlier studies from this laboratory indicated the pres-
ence of b-spectrin in transverse structures overlying the Z
lines and M lines, and in longitudinal strands (62). We
noted that the b-spectrin pattern in muscle from mdx mice
and from patients with Duchenne muscular dystrophy “al-
ways appeared less ordered than in controls” (62). Here
we confirm and extend these earlier observations and
show further that the extent of damage sustained by dys-
trophic myofibers can vary widely. This variability proba-
bly occurs because of differences in contractile activity and
the load experienced in the period before sampling (41, 45,
68, 74), and previous cycles of degeneration and regenera-
tion (14, 19, 53; for review see 22). Therefore, sampling a
large number of myofibers may be necessary to reach any
conclusions about the extent of spectrin-based membrane
skeleton reorganization in dystrophic muscle.
Although much of our research has focused on b-spec-
trin, many other membrane-associated proteins codistrib-
ute with b-spectrin in irregular cytoskeletal arrays found
at the dystrophic sarcolemma. These include all of the fol-
lowing: Na,K-ATPase, present in a complex with spectrin
in skeletal muscle (Williams, M.W., and R.J. Bloch, manu-
script in preparation); utrophin, the dystrophin homo-
logue; two dystrophin-associated proteins, syntrophin and
b-dystroglycan (for review see 9, 55); and vinculin, a pro-
tein normally found at focal adhesions and other plasma-
lemmal sites associated with organized bundles of actin
microfilaments (for review see 11). The fact that all of
these proteins are enriched in costameres of dystrophic
and healthy skeletal muscle suggests that their organiza-
tion is coordinated (however, see 51).
The identity of the protein (or proteins) responsible for
coordinating the distribution of proteins at the sarco-
lemma is still unclear. The most likely candidate is actin
because it binds to dystrophin, b-spectrin, and vinculin,
but the evidence that actin is enriched at costameres is
minimal (12). Furthermore, mutations in dystrophin that
eliminate its actin-binding activity produce mild pheno-
types (9, 10, 84; however, see 3). If the extent of disorgani-
zation of the membrane-associated cytoskeleton is related
to the severity of dystrophinopathy (see below), then the
mild effects of these mutations would argue against a pri-
mary role for actin in coordinating the organization of dys-
trophin and its associated proteins with other membrane
skeletal elements at the sarcolemma.
In contrast, loss of dystrophin’s binding site for dystro-
glycan results in the severest dystrophinopathies (9, 65).
This suggests that dystroglycan or other ligands (e.g.,
g-sarcoglycan; ref. 31) interacting with the COOH-termi-
nal region of dystrophin may be the primary organizers.
For example, syntrophin binds to the voltage-gated so-
dium channel (27) that also associates with spectrin through
ankyrin (72), suggesting that it may link the spectrin-based
membrane skeleton to dystrophin in healthy muscle. How-
ever, as deletion of the syntrophin binding site in the
COOH-terminal region of dystrophin (2) is not associated
with myopathy in mice (65), syntrophin–dystrophin inter-
actions are probably not required to maintain the integrity
of the sarcolemma.
Utrophin, expressed in mdx muscle (42, 46, 48, 86), may
partially substitute for dystrophin at the sarcolemma (79).
Although it concentrates at the sarcolemma and binds to
many of the same ligands as dystrophin, utrophin is un-
likely to organize sarcolemmal spectrin and vinculin. Utro-
phin is present in mdx muscle at levels significantly lower
than the levels of dystrophin in wild-type muscle, but lev-
els of spectrin and vinculin are not appreciably reduced in
mdx muscle (our unpublished observations). Thus, if utro-
phin does help to link the dystrophin-associated cytoskele-
ton to spectrin and vinculin at the sarcolemma, the stoichi-
ometry of this linkage must differ significantly from that
present in normal muscle. Furthermore, although utro-
phin, dystrophin, and spectrin have been shown to codis-
tribute in a membrane skeletal network in cultures of rat
myotubes, this network does not contain vinculin (18, 64;
Bloch et al., manuscript in preparation). These results sug-
gest that utrophin is unlikely to coordinate the organiza-
tion of the various membrane skeletal proteins in mdx
muscle fibers.
Although the proteins that organize the membrane skel-
eton in dystrophic muscle must still be identified, dystro-
phin clearly plays an important role in maintaining the or-
ganization of the membrane skeleton in normal muscle. In
dystrophinopathies, several of the structural domains at
the sarcolemma of wild-type muscle tend to disappear.
However, the nature of the relationship between this reor-
ganization of the membrane skeleton and the absence of
dystrophin in mdx muscle fibers is still not clear.
The reorganization of the membrane skeleton in mdx
myofibers may be an indirect result of the absence of dys-
trophin, perhaps related to changes in Ca21 homeostasis
(21, 33, 36, 44, 66, 78). Ca21-dependent proteases, such as
calpain and caspases, activated by Ca21 entering the myo-
fiber through the dystrophic sarcolemma, are capable ofWilliams and Bloch Reorganization of the Sarcolemma of Dystrophic Myofibers 1268
cleaving spectrins (34, 61, 67, 81) and other structural pro-
teins (29). The proteolysis of spectrin, coupled with the ab-
sence of dystrophin, might disrupt the membrane-associ-
ated cytoskeleton sufficiently to destabilize sarcolemmal
organization. This model predicts an increase in mdx mus-
cle of proteolytic fragments of spectrin, perhaps associated
with the altered costameric structures described here.
Alternatively, the changes in sarcolemmal organization
may not be directly linked to the absence of dystrophin at
all. For example, they may be related to the stage of mus-
cle regeneration reached by each dystrophic myofiber at
the time of sampling. The polygonal arrays seen in a small
percentage of mdx fibers also appear in myofibers devel-
oping in vivo (our unpublished results). However, myofi-
bers in the mdx mouse tend to undergo only a single cycle
of degeneration and regeneration occurring 3–5 wk after
birth. Afterwards, only a small number of muscle fibers
degenerate at any given time (13, 14, 53). As our current
studies were limited to 6-mo-old animals, it is unlikely that
this alone can account for our observation that the mem-
brane skeleton is significantly altered in .90% of mdx
muscle fibers (Fig. 3).
Our results may also be interpreted in terms of models
that invoke a direct role for dystrophin in organizing the
membrane skeleton in healthy muscle fibers. For example,
dystrophin in healthy muscle may stabilize the costameric
sites at which membrane skeletal proteins accumulate.
Therefore, the absence of dystrophin in mdx muscles may
render their membrane skeleton more susceptible to dis-
tortion and disruption by the forces exerted on the sarco-
lemma during muscle contraction and relaxation. This sug-
gests that the membrane domains most easily disrupted at
the sarcolemma are the longitudinal strands and the struc-
tures lying over M lines. These are more readily lost in
mdx muscle, whereas sarcolemmal structures located over
Z lines are more stable. Our previous studies of fast twitch
rat muscle fibers have shown that the domains over Z lines
contain b-spectrin complexed with a-fodrin, whereas the
longitudinal strands and domains over M lines contain
b-spectrin with little a-fodrin or any other a subunit of the
spectrin superfamily that we have been able to identify
(63). Such differences in the structure of membrane-bound
spectrin may account for the greater instability of longitu-
dinal and M line domains in mdx muscle.
Structural differences may also explain why normal con-
tractions lead to damage and degeneration of dystrophic
muscle fibers. The altered organization of costameres sug-
gests that the connections between the sarcolemma and
the sarcomeres of superficial myofibrils are not as periodic
in mdx muscle as they are in controls. In healthy myofi-
bers, these connections mediate the transmission of force
from the contractile apparatus to the sarcolemma and the
extracellular matrix, while keeping the sarcolemma in
close register with the underlying myoplasm during the
contractile cycle (75). The reduced number and the abnor-
mal arrangement of such connections are likely to render
the dystrophic sarcolemma more fragile than controls.
Disruption of the membrane skeleton of mdx also gen-
erates regions of the sarcolemma that are devoid of cos-
tameres. These regions can cover relatively large areas
(.50 mm2; e.g., Fig. 2 H, regions of the sarcolemma be-
tween neighboring Z lines). In normal fast twitch muscle
fibers of the rat, where longitudinal strands and structures
overlying M lines are normally present, the regions be-
tween costameres usually do not exceed 2 mm2 in area, and
even these small regions are likely to be stabilized by low
levels of dystrophin (Williams, M.W., and R.J. Bloch,
manuscript in preparation). This protein is, of course, ab-
sent in mdx muscle. The gaps in the membrane skeleton of
dystrophic myofibers are considerably smaller than the
“delta lesions” documented in samples of Duchenne mus-
cle (52), and unlike delta lesions they appear to be limited
to structures at or immediately adjacent to the sarco-
lemma. Nevertheless, areas lacking a membrane skeleton
may be especially susceptible to damage; indeed, they may
even be the sites at which lesions are initiated. The reorga-
nization of the sarcolemma and the appearance of gaps in
the membrane skeleton may therefore lead directly to the
damage sustained by dystrophic muscle fibers. It follows
that measuring the reduction in the number and size of
these gaps may provide a sensitive and quantitative way to
test therapies now being developed to treat Duchenne
muscular dystrophy.
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